Spots Global Cancer Trial Database for Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
Official Title: A Single Arm, Observational Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment With Sintilimab Injection Plus Endostar in Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
Study ID: NCT03881501
Conditions
Interventions
Study Description
Brief Summary: It is a a single arm, observational clinical trial to evaluate the efficacy and safety of combination treatment with sintilimab injection plus endostar in untreated locally advanced or metastatic hepatocellular carcinoma.
Detailed Description: For the first line treatment with untreated locally advanced or metastatic hepatocellular carcinoma, sintilimab injection plus endostar might be one of the treatment choices.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Tongji Hospital, Wuhan, Hubei, China
Contact Details
Name: Xianglin Yuan, MD,PhD
Affiliation: Tongji Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
